ArticleCell & bioscience2023

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.

Matias A Bustos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.